We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Aurinia Renal Response in Active Lupus With Voclosporin (AURORA)

This study is currently recruiting participants.
Verified November 2017 by Aurinia Pharmaceuticals Inc.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03021499
First Posted: January 16, 2017
Last Update Posted: November 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Aurinia Pharmaceuticals Inc.
  Purpose
The purpose of this study is to assess the efficacy of voclosporin compared with placebo in achieving renal response after 52 weeks of therapy in subjects with active lupus nephritis.

Condition Intervention Phase
Lupus Nephritis Drug: Voclosporin Drug: Placebo Oral Capsule Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis

Resource links provided by NLM:


Further study details as provided by Aurinia Pharmaceuticals Inc.:

Primary Outcome Measures:
  • The number of subjects achieving renal response [ Time Frame: 52 Weeks ]
    The number of subjects achieving renal response


Secondary Outcome Measures:
  • Time to UPCR of ≤0.5 mg/mg. [ Time Frame: 52 Weeks ]
    Time to UPCR of ≤0.5 mg/mg.

  • Partial renal response [ Time Frame: Weeks 24 and 52 ]
    Partial renal response

  • Time to 50% reduction in UPCR from baseline. [ Time Frame: 52 Weeks ]
    Time to 50% reduction in UPCR from baseline.

  • Renal response at Week 52 [ Time Frame: 52 Weeks ]
    Renal response at Week 52

  • Duration of renal response [ Time Frame: 52 Weeks ]
    Duration of renal response

  • Change from baseline in laboratory parameters at each time point [ Time Frame: 52 Weeks ]
    Change from baseline in laboratory parameters at each time point

  • Renal response with low-dose steroids [ Time Frame: 52 Weeks ]
    Renal response with low-dose steroids

  • Quality of Life questionnaires [ Time Frame: Weeks 12, 24 and 52 ]
    Quality of Life questionnaires

  • Change from baseline in the SELENA-SLEDAI Index score [ Time Frame: Weeks 24 and 52 ]
    Change from baseline in the SELENA-SLEDAI Index score


Estimated Enrollment: 324
Actual Study Start Date: May 17, 2017
Estimated Study Completion Date: March 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Voclosporin
oral, 23.7 mg BID
Drug: Voclosporin
calcineurin inhibitor
Other Name: ISA247
Placebo Comparator: Placebo Oral Capsule
Voclosporin placebo, oral, 3 capsules BID
Drug: Placebo Oral Capsule
matching placebo capsule

Detailed Description:
The aim of the current study is to investigate whether voclosporin, added to the standard of care treatment in active lupus nephritis (LN), is able to reduce disease activity over a treatment period of 52 weeks. The background therapy will be MMF and initial treatment with IV methylprednisolone, followed by a reducing course of oral corticosteroids. Subjects with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria (as measured by urine protein/creatinine ratio (UPCR) while demonstrating an acceptable safety profile.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

- Subjects with evidence of active nephritis, defined as follows:

  • Kidney biopsy result within 2 years prior to screening indicating Class III, IV-S, IV-G (alone or in combination with Class V), or Class V LN with a doubling or greater increase of UPCR within the last 6 months to a minimum of ≥1.5 mg/mg for Class III/IV or to a minimum of ≥2 mg/mg for Class V at screening. Biopsy results over 6 months prior to screening must be reviewed with a medical monitor to confirm eligibility.

OR

  • Kidney biopsy result within 6 months prior to screening indicating Class III, IV-S or IV-G (alone or in combination with Class V) LN with a UPCR of ≥1.5 mg/mg at screening.

OR

  • Kidney biopsy result within 6 months prior to screening indicating Class V LN and a UPCR of ≥2 mg/mg at screening.

    • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.

Exclusion Criteria:

  • Estimated glomerular filtration rate (eGFR) of ≤45 mL/minute at screening.
  • Current or medical history of:

    • Congenital or acquired immunodeficiency.
    • In the opinion of the Investigator, clinically significant drug or alcohol abuse within 2 years prior to screening.
    • Malignancy within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.
    • Lymphoproliferative disease or previous total lymphoid irradiation.
    • Severe viral infection or known HIV infection.
    • Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  • Other known clinically significant active medical conditions, such as:

    • Severe cardiovascular disease, liver dysfunction or chronic obstructive pulmonary disease or asthma requiring oral steroids or any other overlapping autoimmune condition for which the condition or the treatment of the condition may affect the study assessments or outcomes.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03021499


Contacts
Contact: Robert Huizinga 250 708 4322 rhuizinga@auriniapharma.com
Contact: Rashieda Gluck rgluck@auriniapharma.com

  Show 125 Study Locations
Sponsors and Collaborators
Aurinia Pharmaceuticals Inc.
Investigators
Principal Investigator: Mary Anne Dooley, MD, MPH University of North Carolina
  More Information

Publications:

Responsible Party: Aurinia Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03021499     History of Changes
Other Study ID Numbers: AUR-VCS-2016-01
First Submitted: January 12, 2017
First Posted: January 16, 2017
Last Update Posted: November 16, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Aurinia Pharmaceuticals Inc.:
lupus nephritis
calcineurin inhibitors
voclosporin

Additional relevant MeSH terms:
Nephritis
Lupus Nephritis
Kidney Diseases
Urologic Diseases
Glomerulonephritis
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Calcineurin Inhibitors
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents